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Bacterial Shiga-like toxins are virulence factors that
constitute a significant public health threat world-
wide, and the plant toxin ricin is a potential bioterror
weapon. To gain access to their cytosolic target,
ribosomal RNA, these toxins follow the retrograde
transport route from the plasma membrane to the
endoplasmic reticulum, via endosomes and the Golgi
apparatus. Here, we used high-throughput screening
to identify small molecule inhibitors that protect cells
from ricin and Shiga-like toxins. We identified two
compounds that selectively block retrograde toxin
trafficking at the early endosome-TGN interface,
without affecting compartment morphology, endoge-
nous retrograde cargos, or other trafficking steps,
demonstrating an unexpected degree of selectivity
and lack of toxicity. In mice, one compound clearly
protects from lethal nasal exposure to ricin. Our
work discovers the first small molecule that shows
efficacy against ricin in animal experiments and iden-
tifies the retrograde route as a potential therapeutic
target.
INTRODUCTION
The plant toxin ricin and the bacterial Shiga toxins are members
of a family of protein toxins that transit along the retrograde
pathway to exert their deleterious effects on eukaryotic cells(Johannes and Popoff, 2008; Lord et al., 2003; Sandvig and
van Deurs, 2005). Ricin from the seeds of the castor oil plant
Ricinus communis is classified as a potential bioterror agent
for which no treatment is available, and, as such, constitutes
a concern for health authorities (Audi et al., 2005). The family of
Shiga toxins includes Shiga toxin produced byShigella dysenter-
iae, and Shiga-like toxins 1 (Stx1) and 2 (Stx2) from enterohemor-
rhagic Escherichia coli strains (for a review, see Johannes and
Ro¨mer, 2010). While Shiga toxin and Stx1 are 99% identical,
Stx1 and Stx2 share only 56% amino acid sequence identity.
Infections with Shiga-like toxin (SLT) producing bacteria can
cause hemorrhagic colitis, hemolytic-uremic syndrome (HUS),
and death (Tarr et al., 2005).
SLTs and ricin are composed of two subunits (Johannes and
Ro¨mer, 2010; Lord et al., 2003). Their A subunits have ribosomal
RNA (rRNA) N-glycosidase activity and catalyze the removal of
the same adenine at position 4324 of 28S rRNA, thereby inhibit-
ing protein biosynthesis. By virtue of their B subunits, these
toxins bind to their cell surface receptors: galactose and N-ace-
tylgalactosamine moieties of glycoproteins and glycolipids for
ricin, and the glycosphingolipid globotriaosyl ceramide (Gb3 or
CD77) in the case of Stx1 and Stx2. After internalization by cla-
thrin-dependent and independent mechanisms, these toxins
are transported from early endosomes to the endoplasmic retic-
ulum (ER), via the Golgi apparatus (Johannes and Ro¨mer, 2010;
Sandvig and van Deurs, 2005). This still poorly explored trans-
port pathway was termed the retrograde route. It is involved in
a number of physiological and pathological situations ranging
from morphogen gradient formations and growth factor traf-
ficking to toxin entry and Alzheimer’s disease (reviewed in
Johannes and Popoff, 2008).Cell 141, 231–242, April 16, 2010 ª2010 Elsevier Inc. 231
Figure 1. High-Throughput Screening for Inhibitors of Ricin
Cytotoxicity
(A) Primary screen of Chembridge library. Library compounds were screened
on A549 human lung carcinoma cells. Yellow dots represent positive controls
(A549 cells treatedwith ricin in presence of 20mM lactose, a competitive inhib-
itor of ricin binding). Green dots are negative controls (A549 cells treated with
ricin only). Red dots correspond to A549 cells incubated with library
compounds in presence of ricin. Retro-1 and Retro-2 are indicated.
(B) Chemical structures of Retro-1 and Retro-2.
(C) Intoxication of A549 cells by ricin in presence of inhibitors. Experimental
conditions are the same as those described for HTS. Cells were incubated
30 min with Retro-1 and Retro-2 before addition of ricin at the indicated
concentrations for 20 hr. Media was removed and replaced with DMEM con-
taining 14C-leucine at 0.5 mCi/ml for 7 hr before counting. Each data point
represents the mean of duplicate ± SD of a representative experiment.
See also Figure S1 and Table S3.A critical step in the retrograde route is the escape from the
endocytic pathway at the level of early endosomes (Mallard
et al., 1998). This retrograde sorting process is highly selective
in that only small quantities of bulk membrane and fluid phase
are targeted nonspecifically from endosomes to the trans-Golgi
network (TGN) (Snider and Rogers, 1985). A large number of
proteins have been shown to be critical (reviewed in Bonifacino
and Rojas, 2006; Johannes and Popoff, 2008). The current
model suggests that clathrin and clathrin-binding proteins such
as epsinR, AP-1, OCRL, and RME-8 are required for the forma-
tion of retrograde tubules on early endosomes. These retrograde
tubules are then processed, involving the retromer complex
(Bonifacino and Hurley, 2008). The fusion of retrograde transport
intermediates with the TGN requires tethering factors such as
golgin-97, GCC88, GCC185, and GARP, SNARE complexes
involving syntaxin 16 and syntaxin 5, and the GTPase Rab6a0.
To date, there is no proven, safe treatment for ricin intoxication
or complicated infections by SLT-producing Escherichia coli
strains other than supportive care (http://emergency.cdc.gov/
agent/ricin/clinicians/treatment.asp; http://www.cdc.gov/nczved/
dfbmd/disease_listing/stec_gi.html). For this, the identification
of compounds that inhibit endocytic toxin trafficking without
exhibiting detrimental effects on cell viability and organelle integ-
rity would be of interest. In this study, we used cell-based high-
throughput screening (HTS) to identify pharmacologically active
compounds able to protect cells from intoxication by ricin and
Stx1 and 2. We identified two compounds capable of blocking
specifically the early endosome-to-TGN toxin transport step
without affecting endogenous retrograde cargo proteins, other
intracellular trafficking pathways, or, more generally, organelle
integrity. One compound, termed Retro-2, clearly protects mice
from intranasal LD90 challenge by ricin and is particularly active
to provide total protection at high doses.
RESULTS
Identification of Ricin Inhibitors by HTS
On the basis of a previously described method (Liger et al.,
1997), a cell-based assay was derived for HTS of ricin inhibitors.
In this assay, the inhibitory effect of ricin on protein biosynthesis
of intact cells is measured through the incorporation of radioac-
tive leucine into neosynthesized polypeptides. We screened for
small molecules that restored normal levels of protein biosyn-
thesis in the presence of ricin, i.e., that inhibited the intoxication
of cells by ricin. HTS was performed on a library of 16,480 drug-
like compounds at a final concentration of 25 mM (Figure 1A).
Twelve compounds provided at least 10% inhibition against
ricin cytotoxicity. By examining the effect of increasing ricin
concentrations on protein biosynthesis in the presence of these
compounds, we confirmed four hits (hit rate of 0.024%) as robust
ricin inhibitors.
For reasons that will be apparent later, two lead compounds
were namedRetro-1 andRetro-2 and chosen for further analysis.
They combined minimal apparent cellular toxicity with robust
activity against ricin and SLTs (see below). Their heterocyclic
structures with central imine or benzodiazepine moieties are
shown in Figure 1B. Given that inhalation is believed to be the
most efficient exposure route to ricin (Audi et al., 2005), their232 Cell 141, 231–242, April 16, 2010 ª2010 Elsevier Inc.protective activity was tested by challenging human pulmonary
carcinoma alveolar basal epithelial A549 cells with increasing
concentrations of ricin under conditions of the HTS assay (Fig-
ure 1C). Both compounds showed significant increases in EC50
values, corresponding to protection factors of 4.6 ± 1.2 standard
deviation (SD; n = 11) for Retro-1 and 3.6 ± 1.1 SD (n = 8) for
Figure 2. Retro-1 andRetro-2 Protect HeLaCells against Ricin, Stx1,
and Stx2
(A–E) Cells were preincubated for 30 min at 37C with DMSO (0.04%; black
data points in all parts of the figure), Retro-1 (20 mM; blue, left column), or
Retro-2 (20 mM; red, right column) before addition of toxin. Intoxication of
HeLa cells by ricin (4 hr) (A), Stx1 (1 hr) (B), Stx1 (4 hr) (C), Stx2 (1 hr) (D), andRetro-2. These experiments show that both compounds partially
protect A549 cells against ricin exposure. A similar protective
effect was observed on HeLa cells (Figure 2A, see below),
demonstrating that compound activity was not restricted to
a specific cell type. No additive or synergistic effects were found
when A549 or HeLa cells were treated simultaneously with both
compounds (Figures S1A and S1B available online). Incubation
of A549 or HeLa cells with 25 mM Retro-1 or Retro-2 for as long
as 4 days did not affect protein biosynthesis (Figures S1C and
S1D), indicating that the compounds were not toxic at the
concentrations used in this study.
No alteration of ricin activity on a 14-mer RNA template
mimicking the toxin’s natural ribosomal RNA substrate was
detected in the presence of Retro-1 and Retro-2 (F. Becher,
E. Duriez and E. Ezan, personal communication). Moreover, pre-
incubation of ricin (or SLTs, see below) with Retro-1 or Retro-2
did not improve the compounds’ protective effect, while it was
found to be necessary to preincubate cells for 30 min with the
compounds to obtain optimal protection (data not shown). These
different sets of data therefore demonstrated that Retro-1 and
Retro-2 do not inhibit the toxins directly. Rather, they appear
to interfere with early stages of toxin entry into cells.
Retro-1 and Retro-2 Strongly Protect HeLa Cells
against SLTs
As ricin shares with SLTs the trafficking via the retrograde route,
we analyzed whether Retro-1 and Retro-2 also protected cells
against these toxins. Protection experiments were performed
on HeLa cells, because A549 cells do not express the Gb3
glycolipid and are thus resistant to SLTs. After pretreatment for
30 min with vehicle alone (0.04% dimethyl sulfoxide [DMSO]),
or with 20 mM Retro-1 or Retro-2, cells were incubated with
increasing concentrations of ricin, Stx1, or Stx2, and protein
biosynthesis was then measured with radiolabeled methionine.
Retro-1 and Retro-2 protected HeLa cells from a 4 hr ricin
challenge (Figure 2A). Ricin toxicity on HeLa cells was reduced
3.6-fold ± 0.1-fold or 2.7-fold ± 0.1-fold (mean ± standard error
of the mean [SEM]) for Retro-1 or Retro-2, respectively (Fig-
ure 2F). These values are similar to those obtained on A549 cells
(Figure 1C).
For SLTs, robust inhibition of protein biosynthesis was
observed on HeLa cells as early as 1 hr after toxin exposure.
At this time (Figures 2B and 2D), or after 4 hr of toxin incubation
(Figures 2C and 2E), Retro-1 (left column) and Retro-2 (right
column) strongly protect cells against Stx1 (Figures 2B and 2C)
and Stx2 (Figures 2D and 2E). Protective indexes between 22
and >100 were measured (Figure 2F). Very clearly, Retro-1 and
Retro-2 inhibit HeLa cell intoxication by ricin, Stx1, and Stx2.
Retro-1 and Retro-2 Specifically Inhibit Retrograde
Transport to the TGN
To analyze whether Retro-1 and Retro-2 affect intracellular toxin
trafficking, we used the B subunit of Stx1, termed STxB, whichStx2 (4 hr) (E) are shown. Eachpoint corresponds to themean±SEMof a repre-
sentative experiment out of two to six determinations.
(F) Protection factors calculated over the indicated number of experiments.
Means ± SEM are shown.
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Figure 3. Retro-1 and Retro-2 Inhibit the Retrograde Transport of
STxB
HeLacellswere pre-incubatedwithDMSO (0.04%), Retro-1 (20mM), or Retro-2
(20 mM) for 30 min at 37C. All subsequent incubations were carried out in the
continued presence of the compounds.
(A) Sulfation assay. After binding, STxB-Sulf2 (1 mM) was incubated with HeLa
cells for 20 min at 37C in the presence of radioactive sulfate. Results repre-
sent means ± SEM of three independent experiments in duplicate. The auto-
radiogram is from a representative experiment.
(B) Endocytosis of STxB-SS-biotin on HeLa cells. Data represent the means ±
SEM (n = 3–4).
234 Cell 141, 231–242, April 16, 2010 ª2010 Elsevier Inc.has been developed as a morphological and quantitative
biochemical tool to study various steps of toxin endocytosis
and retrograde transport (Amessou et al., 2006).
In a first approach, we measured the retrograde transport of
STxB to the TGN using a quantitative biochemical assay. This
assay is based on the use of an STxB variant, STxB-Sulf2, to
which a tandem of protein sulfation sites was added by genetic
fusion. Upon retrograde transport to the TGN, STxB-Sulf2
becomes the substrate of TGN-localized sulfotransferase that
catalyzes the posttranslational transfer of radioactive sulfate
from the medium onto a tyrosyl residue of the recognition
sequence. Detection of sulfated STxB-Sulf2 by autoradiography
thereby allows for the quantification of its retrograde arrival at
the TGN. In cells pretreated for 30 min with 20 mM of Retro-1
or Retro-2, we observed a 80% ± 4% or 82% ± 3% (mean ±
SEM) loss of the sulfation signal compared to vehicle-treated
control cells (Figure 3A). This inhibitory effect persisted for at
least 4 hr (Figure S2A). Importantly, total cellular sulfation levels
(Figure S2B) and STxB binding (Figure S2C) were not affected
on inhibitor-treated cells, demonstrating that sulfotransferase
activity was not perturbed, that cells were in a healthy state
under all conditions, and that the reduced sulfation signal was
not due to reduced amounts of cell-associated STxB.
The inhibition of retrograde transport to the TGN could occur
at the plasma membrane or on endosomes. To address the first
possibility, we quantified the endocytic uptake of STxB in the
presence of Retro-1 or Retro-2 (Figure 3B), by using a conjugate
of STxB to which a biotin was linked via a thiol cleavable disul-
phide bond. The use of a membrane impermeable reducing
agent allowed us to determine the percentage of cell surface
inaccessible (internalized) STxB after various times of incuba-
tion. While preincubation for 30 min with 20 mM Retro-1 or
Retro-2 clearly reduced subsequent transport of STxB to the
TGN (see above), no effect on the internalization of STxB was
detected under these conditions (Figure 3B), suggesting that
both compounds do not exert their inhibitory effect by interfering
with the cellular uptake of STxB.
The biochemical data on the inhibition of STxB transport to the
TGN by Retro-1 and Retro-2 was confirmed in immunofluores-
cence experiments (Figure 3C). Fluorophore-tagged STxB (red)
was bound on ice to vehicle-treated control or compound-
treated cells (conditions as above). After washing, cells were
incubated for 45min at 37C. In control cells, STxB (red) accumu-
lated in perinuclear membranes that were labeled by the Golgi
marker giantin (green; Figure 3C, upper panel). In cells treated
either with Retro-1 (Figure 3C, middle panel) or Retro-2 (Fig-
ure 3C, lower panel), STxB no longer colocalized with giantin but
appeared in peripheral structures that were evenly distributed(C) Incubation of Cy3-STxB (0.5 mg/ml, red) with cells for 45 min at 37C.
The cells were then fixed and labeled for giantin (green). Scale bars represent
10 mm.
(D) Endocytosis of Tf (n = 4).
(E) Recycling of Tf (n = 2).
(F) 125I-EGF-degradation in HeLa cells (n = 4).
(G) Anterograde GFP-VSVGts045 transport at the indicated incubation temper-
atures (n = 3).
In (D–G), means ± SEM are shown. See also Figures S2 and S3.
throughout the cytoplasm. These results confirmed that Retro-1
and Retro-2 block retrograde STxB transport to the TGN/Golgi.
Figure 3C and Figure S3 document that Golgi morphology was
not visibly affected by incubation of cells with Retro-1 or Retro-2,
as judged by giantin labeling. The localization of the Golgi
markers CTR433 and GM130 was also unchanged (Figure S3).
Furthermore, we found that the morphologies of the ER, of early
(EEA1) and recycling endosomes (transferrin receptor [TfR] and
Rab11), and of late endosomes/lysosomes (Lamp1) were unaf-
fected by the compounds.
The specificity of Retro-1 and Retro-2 was further analyzed by
measuring transport via a number of other routes that intersect
with the early endosome-TGN interface: the biosynthetic/secre-
tory, endocytic, and recycling pathways. These were analyzed in
the presence of 20 mM of Retro-1 or Retro-2 (30 min pretreat-
ment), conditions for which it was validated in parallel that
STxB trafficking was strongly inhibited.
As we have seen above, STxB endocytosis was not affected
by Retro-1 or Retro-2 (Figure 3B). On the same cells, the endo-
cytosis of biotinylated transferrin (Tf) was analyzed, with a similar
approach to the one described for STxB. Neither Retro-1 nor
Retro-2 affected the clathrin-dependent endocytic uptake of Tf
(Figure 3D), indicating that this major cellular internalization route
was still operating in the presence of the compounds.
Tf was also used tomeasure recycling from early and recycling
endosomes to the plasma membrane. After an uptake pulse, the
quantity of remaining cell-associated Tf was determined in func-
tion of chase time at 37C (Figure 3E). Again, neither Retro-1 nor
Retro-2 had any effect.
Targeting to the late endocytic pathway was analyzed with
radiolabeled epidermal growth factor (EGF). In interaction with
its receptor, EGF is targeted to late endosomes/lysosomes,
where the protein is degraded. This trafficking from the plasma
membrane into the degrading environment of the late endocytic
pathway was not affected by Retro-1 or Retro-2 (Figure 3F).
Finally, a thermosensitive vesicular stomatitis virus glycopro-
tein mutant fused to green fluorescent protein (GFP-VSVGts045)
was used to assess the effect of Retro-1 and Retro-2 on antero-
grade transport along the biosynthetic/secretory pathway from
the ER to the plasma membrane, via the Golgi apparatus and
the TGN (Figure 3G). In these experiments, GFP-VSVGts045
protein accumulated in the ER at restrictive temperature (40C)
and was then chased at permissive temperature (32C) for
2 hr. The level of GFP-VSVGts045 protein that reached the plasma
membrane in vehicle-treated control cells was set to 100%. In
the presence of brefeldin A, anterograde trafficking was totally
inhibited, and the VSVG trafficking signal was at background
levels, similar to cells that were kept at restricted temperature.
Upon incubation with Retro-1 or Retro-2, GFP-VSVGts045 traf-
ficking was not significantly affected (Figure 3G).
Taken together, these results show that Retro-1 and Retro-2
have no effect on endocytosis, recycling, degradation, and
secretion.
Retro-1 and Retro-2 Treatment Blocks STxB in Early
Endosomes and Relocalizes Syntaxin 5
The peripheral compartments in which STxB accumulated in
Retro-1 and Retro-2-treated cells were further characterized(30min pretreatment with compounds at 20 mM). Amajor overlap
could be found between STxB (red) and TfR (green; Figures 4A
and 4C), a marker of early and recycling endosomes, and
EEA1 (green; Figures 4B and 4D), a marker of early endosomes.
In all these cases, 90% or 85% of TfR or EEA1-positive compart-
ments were also labeled by STxB, respectively. In Retro-1-
(Figure 4E) and Retro-2- (Figure 4F) treated cells, immunogold
labeling on cryosections revealed the presence of STxB (15 nm
gold particles) in tubular and vesicular structures that were
also strongly labeled for TfR (10 nm gold particles), while in
control (Ctr) cells, STxB efficiently accumulated in the Golgi
cisternae (Figure S4A).
The retromer protein Vps26 (green) is also associated with
early endosomes (Arighi et al., 2004), and we found a strong
overlap (75%)with STxB (red) in Retro-1- or Retro-2-treated cells
(Figures S4B and S4E). The overlap between the recycling endo-
somal marker Rab11 (green) and STxB (red) was less important
(50% overlap; Figures S4C and S4F), but still higher than that
observed for the late endosomal marker Lamp1 (green) and
STxB (red; 10% overlap; Figures S4D and S4G), suggesting
that when its retrograde transport to the TGN was inhibited at
the level of early endosomes, STxB in part shifted to recycling
endosomes but failed to reach the late endocytic pathway.
A large number of trafficking factors have been shown to regu-
late retrograde transport at the early endosome-TGN interface
(for a review, see Johannes and Popoff, 2008). Their localization
was analyzed by immunofluorescence microscopy in vehicle-
treated cells and cells that were incubated for 4 hr with 20 mM
of Retro-1 or Retro-2. Strikingly, the SNARE protein syntaxin 5
(green) was strongly relocalized in all compound-treated cells,
while the subcellular distribution of the tethering factor golgin-
97 (red) was not affected (Figure 5A). This robust relocalization
could be detected as early as 30 min after the beginning of
cell exposure to the compounds (Figure 5B). Retro-1 and
Retro-2 did not deplete syntaxin 5 from cells, as determined by
western blotting (data not shown). Syntaxin 5 regulates retro-
grade transport in a complex with Ykt6, GS28, and GS15
(Amessou et al., 2007; Tai et al., 2004). We found that the cellular
distribution of these proteins was not affected by Retro-1 and
Retro-2 (Figure 5C), suggesting that their Golgi localization
is not solely dependent on syntaxin 5. Furthermore, syntaxin 5
is found in two SNARE complexes that are implicated in ER-
Golgi and intra-Golgi transport: Syntaxin5/GS27/Bet1/Sec22b
and Syntaxin5/GS28/Bet1/Ykt6 (Hay et al., 1998; Zhang and
Hong, 2001). In cells treated with Retro-1 or Retro-2, GS27
localization was not altered (Figure 5D), again suggesting that
interactions with other Golgi proteins dictate localization to Golgi
membranes.
Syntaxin 6 was also displaced by Retro-1 and Retro-2 treat-
ment of cells (Figure 5E), even if at 4 hr of compound treatment
the effect appeared somewhat smaller than for syntaxin 5. At
30 min of treatment, only very few cells displayed a partially
redistributed syntaxin 6 labeling pattern (Figure 5F). Since under
the same conditions syntaxin 5 was already strongly affected
(see above, Figure 5B), it is possible that the effect on syntaxin
6 is secondary to that on syntaxin 5. For the syntaxin 6 SNARE
interacting partner syntaxin 16, a weak relocalization phenotype
was observed at 4 hr of compound treatment, while the otherCell 141, 231–242, April 16, 2010 ª2010 Elsevier Inc. 235
Figure 4. STxB Accumulates in Early Endosomes on
Retro-1- or Retro-2-Treated Cells
(A–F) In all conditions, HeLa cells were preincubated for 30min
at 37C with 20 mM of Retro-1 (A, B, and E) or Retro-2 (C, D,
and F). All subsequent incubations were carried out in the
continued presence of the compounds.
(A–D) After binding of Cy3-STxB (0.5 mg/ml, red) to cells on ice
and washing, the cells were incubated for 45 min at 37C,
fixed, and labeled for the indicated proteins (green). Magnifi-
cation views of boxed areas are shown on the right. Scale
bars represent 10 mm.
(E and F) After binding of STxB (0.5 mM) to cells on ice and
washing, the cells were incubated for 45 min at 37C, fixed,
and submitted to ultrathin cryosectioning. Sections were
labeled with anti-STxB (15 nm gold particles) and anti-TfR
(10 nm gold particles) antibodies and protein A gold conju-
gates. Scale bars represent 200 nm.
See also Figure S4.partners of this SNARE complex that regulates retrograde trans-
port at the early endosome-TGN interface, VAMP4 and Vti1a
(Mallard et al., 2002), were not affected (Figure 5G).
The effect of Retro-1 and Retro-2 on syntaxin 5 was very
specific. Indeed, the localization of none of the following retro-
grade trafficking factors was affected (Figure S5): clathrin light
chain and clathrin heavy chain isoform CHC22; clathrin adaptors
AP-1, AP-3, and epsinR; PACS-1 and PACS-2; retromer proteins
Vps26, SNX1, and SNX2; GTPases Rab6 and Rab9; tethering236 Cell 141, 231–242, April 16, 2010 ª2010 Elsevier Inc.factors golgin-97, p230, GCC185, and GCC88;
and SNARE protein syntaxin 10. Furthermore, two
tests revealed that phosphatidylinositol 3-phos-
phate (PI3P) metabolism was not affected by the
compounds. First, we expressed the GFP-tagged
FYVE domain of EEA1 that specifically recognizes
PI3P (Hunyady et al., 2002). Retro-1 and Retro-2
did not affect the early endosomal localization of
the probe, while the phosphatidylinositol 3-kinase
(PI-3K) inhibitor wortmannin led to a strong relocal-
ization (Figure S6A). Second, a Jurkat cell line with
permanently activated PI-3K was transfected with
a GFP-tagged PH domain construct of Akt kinase
that recognizes elevated PI(3,4,5)P3 levels at the
plasma membrane (Astoul et al., 2001). Again,
Retro-1 and Retro-2 had no effect on PH domain
localization to the plasma membrane, while the
PI-3K inhibitor LY294002 as a positive control
induced a strong redistribution to the cytosol (Fig-
ure S6B).
Retro-1 and Retro-2 Have No Effect on
Endogenous Retrograde Cargo Proteins
Several exogenous and endogenous cargo pro-
teins share with STxB elements of retrograde trans-
port machinery for their efficient trafficking between
early endosomes and the TGN (summarized in
Johannes and Popoff, 2008). Thus, we examinedwhether Retro-1 and Retro-2 affected the retrograde transport
of these cargoes.
Like Shiga toxin, cholera toxin is composed of a catalytic A
subunit and a homopentameric B subunit (CTxB), which binds
to a glycosphingolipid, and is internalized to the ER and the
cytosol via the retrograde route (Sandvig et al., 2004). CTxB
(green; Figure 6A, top panel) was fluorophore labeled and
accumulated in perinuclear Golgi membranes (giantin, blue)
after 45 min incubation with HeLa cells. Similar to STxB, the
Figure 5. Retro-1 and Retro-2 Relocalize Syntaxin 5
Cells were treated for 4 hr (A, C, D, E, and G) or 30 min (B and F) with carrier (0.04% DMSO), Retro-1 or Retro-2 (20 mM), fixed, and labeled for the indicated
proteins. Note the strong relocalization of syntaxin 5 that can clearly be seen after only 30 min of compound treatment. For syntaxin 6, the relocalization pheno-
type appears weaker and is observed systematically only at the 4 hr time point. Scale bars represent 10 mm. See also Figures S5 and S6.accumulation of CTxB in perinuclear Golgi membranes was
strongly reduced in cells that were pretreated for 30 min with
20 mMRetro-1 (Figure 6A, middle panel) or Retro-2 (lower panel),
demonstrating that the cellular entry of this toxin subunit was
also blocked.
The cation-independent mannose 6-phosphate receptor
(CI-MPR) shuttles newly synthesized mannose 6-phosphate-
tagged lysosomal enzymes from the TGN to the endosomal
pathway and then returns to the TGN to retrieve additional cargo
(Ghosh et al., 2003). Convergent evidence has been presented
on a role in retrograde CI-MPR transport for the trafficking
machinery involved in STxB uptake, even if additional complexity
exists (summarized in Johannes and Popoff, 2008). In a first
approach to assess the effect of Retro-1 and Retro-2 on CI-MPR
trafficking, we used a cell line that expresses a GFP-tagged
CI-MPR transgene (Waguri et al., 2003). Retrograde CI-MPRtransport from the plasma membrane to the TGN can be fol-
lowed in these cells with an antibody uptake assay that consists
of adding an anti-GFP antibody into the culture medium. The
antibody binds to GFP-CI-MPR at the cell surface and is then
retrieved to the TGN with its antigen (Amessou et al., 2006). In
the vehicle-treated control cells (Figure 6B, upper panel), the
antibody (aGFP, blue) accumulated within 40 min in the perinu-
clear Golgi region, where it colocalized with STxB (red) and the
bulk GFP fluorescence (green). Importantly, in cells that were
pretreated for 60 min with 20 mM Retro-1 (middle panel) or
Retro-2 (lower panel), STxB transport was strongly impaired,
as described above, but the anti-MPR antibody still reached
the perinuclear Golgi membranes as efficiently as in control cells,
suggesting that both compounds selectively affected retrograde
toxin trafficking only. In additional experiments (Figure 6C), we
found that even after incubations for as long as 6 hr, 20 mMCell 141, 231–242, April 16, 2010 ª2010 Elsevier Inc. 237
Figure 6. Effects of Retro-1 and Retro-2 on the Retrograde Transport of Various Cargo Proteins
In all conditions, HeLa cells were treated with DMSO (0.04%; control) Retro-1, or Retro-2 (20 mM). For incubation periods, see below.
(A) CTxB trafficking (preincubation of 30 min). After binding, Alexa488-CTxB (4 mg/ml, green) was incubated with HeLa cells for 45 min at 37C. The cells were
fixed and labeled for giantin (blue). Note that CTxB is blocked in peripheral structures in compound-treated cells.
(B) Antibody uptake assay for CI-MPR (preincubation of 60 min): HeLa cells stably expressing GFP-CI-MPR (green) were allowed to internalize surface-bound
Cy3-STxB (red) in the presence of anti-GFP antibody (blue) for 40min at 37C. Note that the anti-GFP antibody is efficiently transported to the Golgi, in contrast to
STxB.
(C) Steady-state localization of CI-MPR: HeLa-cells were incubated with Retro-1 or Retro-2 (20 mM) for 51⁄2 hours at 37
C. After binding of Cy3-STxB (red), cells
were incubated for another 45 min at 37C. The cells were then fixed and labeled for CI-MPR (green) and giantin (blue).
(D) Steady-state localization of TGN46: Cells were treated as in Figure 6C, and labeled for TGN46 (green) and giantin (blue).
Scale bars represent 10 mm.Retro-1 (middle panel) andRetro-2 (lower panel) only had aminor
effect on the steady-state distribution of endogenous CI-MPR
(green), while STxB (red) transport was strongly inhibited.
TGN46 is another well-studied retrograde cargo protein of
unknown function that like STxB traffics between early endo-
somes and the TGN (Ghosh et al., 1998; Mallard et al., 1998).
As for CI-MPR, we found that the steady-state distribution of
TGN46 (green; Figure 6D) was not affected by a 6 hr cell treat-
ment with 20 mM of Retro-1 (middle panel) or Retro-2 (lower
panel). Again, it was validated that STxB (red) trafficking was
inhibited under these conditions. Clearly, both inhibitors are
selective for the retrograde trafficking of exogenous toxins that238 Cell 141, 231–242, April 16, 2010 ª2010 Elsevier Inc.we have tested here, and do not affect endogenous CI-MPR
and TGN46.
Retro-1 and Retro-2 Protect Mice against Intoxication
by Ricin
We have found that Retro-1 and Retro-2 selectively inhibit
cellular toxin uptake without affecting compartment integrity,
endogenous retrograde cargo transport, and a number of other
trafficking events. Encouraged by this selectivity, we analyzed
whether these compounds could be used to protect mice
against lethal ricin challenges. Retro-1 and Retro-2 were non-
toxic for animals after intraperitoneal administration of up to
Figure 7. Retro-2 Protects Mice against Ricin Challenge
Comparison of survival curves of mice that were treated with various doses of
Retro-2 and then exposed to ricin via the nasal route. In each experiment,
treated animals received a single dose of Retro-2 intraperitoneally 1 hr prior
to toxin exposure (2 mg/kg by nasal instillation), while control animals received
vehicle only prior to ricin administration. The curves for treated animals
are statistically different from control as measured by the log rank test (p <
0.0001 for 2 mg/kg of Retro-2, orange; p = 0.015 for 10 mg/kg, brown; p =
0.031 for 20 mg/kg, purple; p = 0.0007 for 200 mg/kg, red). See also
Figure S7 and Tables S1 and S2.400mg/kg (Table S1). Amodel of ricin intoxication by nasal instil-
lation was developed to mimic exposure by aerosols, a likely
modality in bioterror attacks (http://emergency.cdc.gov/agent/
ricin/). In this model, a dose of ricin leading to 90% deaths at
day 21 (LD90) was used (Figure 7, black curve). The first clinical
signs of intoxication appeared within 24 hr. All the mice first
got bristly and greasy hairs. From day 2, loss of body weight
was observed. At later time points other symptoms were noticed
such as prostration, shaking, and respiratory distress, and
animals needed to be sacrificed starting from day 7 after expo-
sure. A strong and statistically highly significant protection was
observed with a single dose of 2 mg/kg of Retro-2 injected intra-
peritoneally 1 hr prior toxin challenge (Figure 7, orange curve).
Forty-nine percent (n = 45; five independent experiments) of
Retro-2-injected mice survived (p = 0.001), while in the control
group, survival was as low as 11.5% (n = 130, 10 independent
experiments). Comparison of survival curves also showed a
significant difference (Figure 7; p < 0.0001). On the basis of
this robust result, complementary experiments were performed
with exploratory doses of Retro-2. Survival of mice followed
a dose-response relation. Administration of 10 mg/kg (brown
curve) and 20 mg/kg (purple curve) of Retro-2 also gave statisti-
cally significant levels of protection, compared to the control
group (p = 0.015, n = 10 and p = 0.031, n = 5, respectively),
resulting in 60% survival at 20 days (Figure 7). Finally, 200 mg/kg
of Retro-2 fully protected mice against ricin challenge (p =
0.0007, n = 5) (Figure 7, red curve). Survival curves are shifted
toward higher survival numbers according to Retro-2 dose
increase. Similarly, the median mortality, at which 50% deaths
were observed, is delayed according to dose. These medians
were for control, day 12; and for Retro-2 at 2 mg/kg, day 14,
and at 10 mg/kg, day 21. At 20 and 200 mg/kg, the value could
not be determined because mortality was less than 50%.The results obtained in vivo with Retro-1 were more difficult to
interpret but nevertheless showed some protection with the
lowest dose that was used in this study (0.5 mg/kg, blue curve;
Figure S7). In this condition, three out of five mice survived, while
all of the 14 mice of the control group died (p = 0.014). Retro-1
did not have a protective effect at doses of 2, 10, 20, and 200
mg/kg (Figure S7).
In conclusion, we demonstrate that a small molecule can
protect animals exposed to a lethal dose of ricin, thereby identi-
fying Retro-2 as a lead compound for the development of inhib-
itors of toxins that follow the retrograde route.
DISCUSSION
In this study, we used a cell-based HTS assay to identify chem-
ical inhibitors of cell intoxication by ricin. Two compounds with
efficacy against both ricin and SLTs were selected. These mole-
cules do not act on the toxins themselves. Rather, they inhibit
retrograde transport between early endosomes and the TGN.
Such protection of one drug (our small molecule inhibitors)
against the action of another (ricin or SLTs) falls under the
general phenomena of suppressive drug interactions (Fraser,
1872; Yeh et al., 2009). Obtaining broad-spectrum drugs acting
on the host instead of the pathogen may have several advan-
tages: (1) usefulness against new emerging pathogens, (2) new
possibilities to act on known pathogens that have become resis-
tant to existing drugs, and (3) reduced risk of acquisition of resis-
tance. The latter point is related to the fact that the pathogen
would need to develop a novel mechanism of action to escape
the cell-based inhibitor, requiring many adaptive mutations.
The chemical compounds that we have identified, Retro-1 and
Retro-2, possess exquisite specificity for the toxins that we have
tested. How this specificity is achieved is not yet understood.
Nevertheless, one can hypothesize that glycolipids may be
involved. Glycolipids indeed are the cellular receptors of SLTs
and cholera toxin (Holmgren et al., 1973; Jacewicz et al., 1986)
and are required for their internalization and intracellular traf-
ficking (Sandvig et al., 2004). Even if the role of glycolipids in ricin
intoxication has been questioned (Spilsberg et al., 2003), other
data suggest that they may contribute to the process, in addition
to glycoprotein receptors (Lord et al., 2003). When toxins are
bound to glycolipids, they interact only with the exoplasmic
leaflet of the membrane. In contrast, the endogenous proteins
TGN46 (Ponnambalam et al., 1996) and CI-MPR (Glickman
et al., 1989) that are not affected by Retro-1 or Retro-2 depend
on sorting signals in their cytosolic tails for proper intracellular
trafficking. Such disparity between the glycolipid toxin receptors
and endogenous protein cargos may explain the difference of
susceptibility to Retro-1 and Retro-2. Other explanations such
as distinct molecular trafficking requirements must also be
considered.
Retro-1 and Retro-2 did not show any additive or synergistic
effect, and it is therefore likely that they share a common
target. As a first step to target identification, we have screened
Retro-1 and Retro-2 for effects on the localization of trafficking
machinery at the endosome-TGN interface. Of note, among
the 26 factors that have been analyzed, only syntaxin 5 and, to
a lesser extent, syntaxin 6 were relocalized from their normalCell 141, 231–242, April 16, 2010 ª2010 Elsevier Inc. 239
site of accumulation on perinuclear Golgi membranes. Both of
these SNAREs have previously been implicated in the retrograde
toxin transport to the TGN (Mallard et al., 2002; Nishimoto-Morita
et al., 2009; Tai et al., 2004), and, in agreement with earlier find-
ings (Amessou et al., 2007), we observed here that Shiga toxin
was blocked in early endosomes in cells in which syntaxin 5
activity was altered. Whether these SNAREs are direct targets
of Retro-1 and Retro-2 and whether their relocalization is directly
responsible for the transport inhibition still need to be estab-
lished. To the least, these findings confirm the exquisite speci-
ficity of the inhibitory compounds, provide important leads for
target identification, and further establish the early endosome-
TGN interface as the site of action of Retro-1 and Retro-2.
Some small molecules have already been identified that inhibit
retrograde transport of toxins, such as brefeldin A (Donta et al.,
1995), Exo2 (Feng et al., 2004), Golcidide A (Sa´enz et al.,
2009), and others (Saenz et al., 2007). These compounds rapidly
affect compartment morphology, and their effects on trafficking
are limited neither to the retrograde route nor to toxins. Animal
data have yet to be reported for these compounds.
On cells, Retro-1 and Retro-2 have amuch stronger protective
effect against SLTs than against ricin. Most likely, ricin can
use several mechanisms to traffic between endosomes and
the TGN, by binding to a variety of receptors. In contrast, Stx1
and Stx2 only bind to Gb3, and, within a given cell type, may
be facing limited molecular redundancy for reaching TGN mem-
branes. Ricin has also been proposed to cross endosomal
membranes to reach the cytosol, as an alternative mechanism
to retrotranslocation from the ER (Beaumelle et al., 1993). This
type of endosomal escape would allow bypassing the retrograde
transport requirement.
One of the most striking findings of the current manuscript is
the Retro-2-mediated protection of mice from a lethal ricin chal-
lenge. Retro-2 therefore appears as a promising candidate for
the further development as an antiricin drug. Interfering with ricin
after an initial exposure may be of medical interest as ricin prog-
resses through tissues over several days (Cook et al., 2006). In
addition, antibodies against ricin can protect mice when admin-
istered up to 24 hr after an initial ricin exposure (Pratt et al., 2007).
A surprising result is that Retro-2 is able to protect mice
against lethal ricin challenge while its protective factor on cells
is only around 3. This may be explained by the steepness of
the toxicity curve in mice. Indeed, protection experiments were
conducted at 2 mg/kg of ricin per mice, corresponding to one
LD90 (Figure 7), while in toxicity assay all mice survived at 1 mg/kg
(Table S2). Thus, at LD90, a small reduction of toxin efficacy may
lead to efficient protection.
At this stage, the reason why in mice Retro-1 does not confer
the same protection against ricin as Retro-2 is unclear. Since
Retro-1 and Retro-2 were both equally potent at inhibiting retro-
grade transport and cell intoxication, we suspect that differences
in biodistribution and/or pharmacokinetics are responsible for
the limited in vivo activity of Retro-1. One must consider that
Retro-1 and Retro-2 are nonoptimized hits and that chemical
engineering may further improve their in vivo activity.
In the case of SLTs, disease leading to life-threatening hemo-
lytic-uremic syndrome develops over days (Tarr et al., 2005), and
to date no proven safe treatment exists for infection by SLT-240 Cell 141, 231–242, April 16, 2010 ª2010 Elsevier Inc.producing E. coli strains and the prevention of SLT-mediated
complications, other than supportive care. Moreover, the use
of antibiotics seems to exacerbate the disease, possibly by
inducing bacterial lysis and increased release of toxins. There-
fore, the development of Retro-2 may also be of interest in this
pathology. More generally, our study identifies the retrograde
route as a potential therapeutic target for the prevention of path-
ological manifestations that are caused by a variety of toxins that
rely on retrograde trafficking to reach their intracellular targets.
Among the most prominent of these toxins are ricin, SLTs, and
cholera toxin from Vibrio cholerae as shown here, but also
exotoxin A from Pseudomonas aeruginosa and subtilase cyto-
toxin and heat-labile enterotoxin from E. coli.
EXPERIMENTAL PROCEDURES
A list of chemicals and materials can be found in the Extended Experimental
Procedures.
High-Throughput Screening
The HTS assay protocol is described in detail in the Extended Experimental
Procedures. In brief, A549 cells were grown in Cytostar T scintillating micro-
plates (GE) with incorporated scintillator. Ricin was added to each well
of library compounds microplates. The commercial Chembridge DIVERset
library, consisting of 16,480 compounds that were tested at a final concentra-
tion of 25 mM, was screened. The mix was then transferred onto the cells (final
ricin concentration: 1010M). After 20 hr, cells were grown for an additional 7 hr
in the presence of 14C-leucine. Data were normalized as percentage inhibitor
relative to positive control. Active compounds were defined as those exhibiting
an inhibiting activity of greater than 10%. The most efficient concentrations of
active compounds were defined as those that exhibit the best cellular protec-
tion index (EC50drug/EC50toxin ratio) without exhibiting cytotoxicity.
HeLa Cells and Intoxication Assay
HeLa cells were maintained at 37C under 5% CO2 in Dulbecco’s modified
Eagle’s medium (DMEM; Invitrogen) supplemented with 10% fetal bovine
serum, 4.5 g/l glucose, 0.01% penicillin-streptomycin, 4 mM glutamine, and
5 mM pyruvate. HeLa cells were seeded at 20,000 cells per well in 96-well
plates and grown overnight. After incubation with 20 mM of compound (or
0.04%DMSO) for 30 min at 37C, cells were challenged with increasing doses
of ricin (4 hr), Stx1, or Stx2 (1 or 4 hr), in the continued presence of compounds.
Protein biosynthesis was determined 1 hr later by measuring the incorporation
of radiolabeled methionine into acid-precipitable material, as previously
described (Amessou et al., 2007).
The mean percentage of protein biosynthesis was determined and normal-
ized from duplicate wells. All values are expressed as means ± SEM. Data
were fitted with Prism v5 software (Graphpad, San Diego, CA) to obtain the
50% effective toxin concentration (EC50). EC50 values and protection factor
(i.e., EC50 ratio = EC50drug/EC50toxin) were determined by the nonlinear
regression dose-response EC50 shift equation. The goodness of fit for each
toxin and drug was assessed by R2 and confidence intervals.
Immunofluorescence and Electron Microscopy
For immunofluorescence experiments, compound-treated cells were first
incubated with Cy3-STxB (0.5 mg/ml) or Alexa488-CTxB (4 mg/ml) for 30 min
on ice, followed by 45 min at 37C in the continued presence of compounds
(20 mM). Cells were fixed, immunolabeled with antibodies corresponding to
the indicated proteins, and imagedwith a Leica TCS SP2 confocal microscope
with HCX PL APO objectives (1003/1.40–0.7 and 633/1.32–0.60, LeicaMicro-
systems, Mannheim, Germany). Maximum projections of six to eight optical Z
slices (300 nmZ separation) are shown. Overlapwas quantified for each condi-
tion on 6 cells on a total of 200–300 structures by determining the fraction of
compartment marker-positive structures that were also labeled for STxB.
For electronmicroscopy, control cells or cells treated for 30min at 37Cwith
20 mM of Retro-1 or Retro-2 were put on ice, incubated for 30 min with 0.5 mM
of STxB, and then shifted for 45 min to 37C. The latter two steps were done in
the continued presence of the compounds. The cells were fixed with a mixture
of 2% PFA and 0.2% glutaraldehyde in 0.1 M phosphate buffer (pH 7.4) and
processed for ultracryomicrotomy and double-immunogold labeled with
protein A conjugated to 10 nm gold (PAG10) or 15 nm gold (PAG15). Sections
were observed under an electron microscope (Philips CM120; FEI Company),
and digital acquisitions were made with a numeric camera (Keen View; Soft
Imaging System).
Sulfation Assay
The sulfation assay was performed as previously described (Amessou et al.,
2006). In brief, a STxB variant termed STxB-Sulf2 that bears a tandem of
protein sulfation recognition sites was bound to cells on ice. After washing,
the cells were incubated for 20 min at 37C in the presence of 35S-sulfate
(480 mCi/ml), STxB was immunoprecipitated, and sulfation was quantified by
autoradiography.
Endocytosis and Recycling Assays
STxB and Tf were biotinylated with NHS-SS-biotin as previously described
(Amessou et al., 2006). Compound-treated (20 mM, 30 min at 37C) HeLa cells
were detached with 2 mM EDTA/PBS, followed by the incubation with STxB-
SS-biotin (5 mg/ml) and Tf-SS-biotin (20 mg/ml) on ice. After washing, cells were
incubated at 37C for the indicated times. Biotin on surface-exposed STxB-
SS-biotin and Tf-SS-biotin was cleaved on ice by treatment with the non-
membrane-permeable reducing agent MESNA (2-mercaptoethansulfonic
acid, 100 mM). Under these conditions, internalized STxB-SS-biotin and
Tf-SS-biotin are protected against reductive cleavage. After inactivation of
MESNA with iodoacetamide (150 mM) and cell lysis, biotinylated STxB and
Tf were quantified by ELISA with anti-STxB mAb 13C4, anti-Tf mAb H68.4,
and streptavidin-HRP.
Recycling of Tf was determined as follows: HeLa cells were incubated with
Tf-SS-biotin (40 mg/ml) for 60 min at 37C. The cells were washed, and incuba-
tion was continued at 37C for the indicated times in the absence of Tf-SS-
biotin. The remaining cell-associated biotinylated Tf was quantified at each
time point by ELISA, as described above.
EGF Degradation
125I-EGF was bound on ice to compound-treated (20 mM, 30min at 37C) HeLa
cells. After incubation in the continued presence of the compounds for the indi-
cated times at 37C in serum-free HEPES culture medium, TCA-precipitable
counts were determined in culture medium and cell lysates, essentially as
described (Mallard et al., 1998). One hundred percent indicates the quantita-
tive transformation of 125I-EGF into TCA soluble counts.
Anterograde VSVG Transport
The anterograde transport of GFP-VSVGts045 was measured on control and
compound-treated cells, as described (Amessou et al., 2007). In brief, cells
were transfected with an expression plasmid containing GFP-VSVGts045
cDNA, using a calcium phosphate transfection kit (Invitrogen) and incubated
overnight at nonpermissive temperature (40C). Under these conditions, the
misfolded protein accumulates in the ER. Subsequently, detached cells
were treated with carrier (0.04% DMSO), Retro-1 (20 mM), Retro-2 (20 mM),
or brefeldin A (18 mM) for 30 min at 37C. VSVG folding and subsequent trans-
port of the folded protein to the Golgi apparatus and plasma membrane was
initiated by shifting cells to 32C in the presence of compounds. Expression
at the plasma membrane was quantified 2 hr later by flow cytometry on a
FacsCalibur multipurpose flow cytometer with an antibody directed against
the extracellular domain of VSVG.
In Vivo Experiments
Animal studies were done at French Health Products Safety Agency (Afssaps)
animal care facility and in compliance with Afssaps committee policies
according to European regulations. Pathogen-free 6-week-old female Balb/c
mice were purchased from Charles River Laboratories (L’Arbresle, France).
Experiments were performed according to good laboratory practice, ISO
17025 standard, and the guide for the care and use of laboratory animals. Envi-
ronmental parameters are in accordancewith European directive 86/609/CEE.Mice were housed under a 12 hr light-dark cycle and fed a standard diet ad
libidum. Standardized groups of mice were injected intraperitoneally with
500 ml of sterile saline solution (0.9% NaCl) supplemented with 1%–10%
DMSO alone (control) or with various doses of Retro-1 or Retro-2 one hour
prior to toxin administration.
Mice were anesthetized by intraperitoneal injection (100 mL) of ketamine
(1.15 mg final) -rompun (xylazine, 0.28 mg final) solution and exposed to
50 ml of ricin (2 mg/kg) by intranasal instillation corresponding to one LD90 at
day 21. Each drug-treated group contained five to ten mice, and normal
controls contained ten mice. Survival was recorded daily.
Data for mice in each test group were compared to those for untreated ricin-
challenged mice by the log rank test (Prism, Graphpad, San Diego, CA), and
p values% 0.05 were considered statistically significant.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and three tables and can be found with this article online at doi:10.
1016/j.cell.2010.01.043.
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